stonks4u
Sign up free
IGC logo

IGC IGC Pharma, Inc.

New York Stock Exchange Arca · Biotechnology · Healthcare

$0.30
+0.00 (+1.29%)

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dement…

Market Cap: $29.81Migcpharma.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

60
60
Aug 11Aug 11

Quote

Day Range
$0.29 – $0.30
52-Week Range
$0.24 – $0.50
Volume
$1.53M
Market Cap
$29.81M
50-Day Avg
$0.27
200-Day Avg
$0.30
Prev Close
$0.29
Open
$0.30

Valuation & Ratios

P/E Ratio
-3.64
EPS
$-0.07
P/B Ratio
4.08
P/S Ratio
21.08
Debt/Equity
0.15
Current Ratio
0.40
Dividend Yield
+0.0%
Gross Margin
+29.7%

Returns & Efficiency

Return on Equity
-107.0%
Return on Assets
-71.3%
FCF Yield
-24.4%
EV/EBITDA
-4.13

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2026$1.19M$-6.55M$-0.07
2025$1.27M$-7.12M$-0.09
2024$1.34M$-13.00M$-0.22
2023$911.0K$-11.51M$-0.22
2022$397.0K$-15.02M$-0.30

Social Signal Score

10
5d
10
1 mentions
—
30d
10
1 mentions
—
60d
10
1 mentions
—
90d
10
1 mentions
—
news: 1

Earnings

Fri, Nov 13(in 3 months)

Consensus estimate $-0.02 per share

6of 7 quarters beat consensus

Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 14$-0.03 vs $-0.02miss
  • Fri, May 15$-0.02 vs $-0.02beat
  • Fri, Apr 3$-0.02 vs $-0.02beat
  • Fri, Nov 14$-0.02 vs $-0.02beat
  • Tue, Aug 19$-0.02 vs $-0.03beat
  • Mon, Jun 30$-0.02 vs $-0.02beat

Estimates and results for IGC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

IGChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsaccessnewswire.com·4d ago·Negative

    IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development ca

    View source ↗